Photosensitizing activity of hypericin and hypericin acetate after topical application on normal mouse skin

British Journal of Dermatology

Volumn 158, Issue 2, 2008, Pages 360-369

  Boiy, A ^a   Roelandts, R ^b   Van Den Oord, J ^a   De Witte, P A M ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Fluorescence microscopy; Hypericin; Hypericin acetate ester; Photodynamic therapy; Phototoxicity; Topical application

Indexed keywords

AMINOLEVULINIC ACID METHYL ESTER; HYPERICIN; HYPERICIN ACETATE; PHOTOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG PENETRATION; DRUG RETENTION; EAR; EPIDERMIS; ERYTHEMA; FEMALE; FLUORESCENCE MICROSCOPY; IRRADIATION; MALE; MOUSE; NONHUMAN; PHOTODYNAMIC THERAPY; PHOTOTOXICITY; PRIORITY JOURNAL; SCAR FORMATION; SKIN PENETRATION; SKIN TOXICITY; SWELLING; TISSUE REPAIR; TOPICAL TREATMENT;

ADMINISTRATION, TOPICAL; AMINOLEVULINIC ACID; ANIMALS; DERMATITIS, PHOTOTOXIC; FEMALE; MALE; MICE; MICE, INBRED BALB C; PERYLENE; PHOTOSENSITIZING AGENTS; RADIATION-SENSITIZING AGENTS; SKIN; TIME FACTORS;

EID: 38349144276     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2007.08329.x     Document Type: Article

References (39)

1. Moore DE. Drug-induced cutaneous photosensitivity. Drug Saf 2002 25 : 345 72.
2. Roelandts R. Wat is nieuw op het gebied van fotosensibilisatie? Tijdschr voor Geneesk 1997 53 : 573 7.
3. Henderson BW, Dougherty TJ. How does photodynamic therapy work? Photochem Photobiol 1992 55 : 145 57.
4. McCaughan JS Jr. Photodynamic therapy: a review. Drugs Aging 1999 15 : 49 68.
5. Dolmans DEJGJ, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer 2003 3 : 380 7.
6. Kurwa HA, Barlow RJ. The role of photodynamic therapy in dermatology. Clin Exp Dermatol 1999 24 : 143 8.
7. Morton CA, Brown SB, Collins S et al. Guidelines for topical photodynamic therapy: report of a workshop of the British Photodermatology Group. Br J Dermatol 2002 146 : 552 67.
8. Taylor EL, Brown SB. The advantages of aminolevulinic acid photodynamic therapy in dermatology. J Dermatol Treat 2002 13 : S3 11.
9. Peng Q, Warloe T, Moan J et al. Distribution of 5-aminolevulinic acid-induced porphyrins in noduloulcerative basal cell carcinoma. Photochem Photobiol 1995 62 : 906 13.
10. Giese AC. Hypericism. Photochem Photobiol Rev 1980 5 : 229 55.
11. Gulick RM, McAuliffe V, Holden-Wiltse J et al. Phase I studies of hypericin, the active compound in St John's wort, as an antiretroviral agent in HIV-infected adults. Ann Intern Med 1999 130 : 510 14.
12. Jacobson JM, Feinman L, Liebes L et al. Pharmacokinetics, safety, and antiviral effects of hypericin, a derivative of St John's wort plant, in patients with chronic hepatitis C virus infection. Antimicrob Agents Chemother 2001 45 : 517 24.
13. Boiy A, Roelandts R, Roskams T, de Witte PAM. Effect of vehicles and esterification on the penetration and distribution of hypericin in the skin of hairless mice. Photodiagnosis Photodynamic Ther 2007 4 : 130 9.
14. Falk H, Meyer J, Oberreiter MA. Convenient semisynthetic route to hypericin. Monatsh Chem 1993 124 : 339 41.
15. Gross E, Ehrenberg B, Johnson FM. Singlet oxygen generation by porphyrins and the kinetics of 9,10-dimethylanthracene photosensitization in liposomes. Photochem Photobiol 1993 57 : 808 13.
16. Wilkinson F, Helman WP, Ross AB. Quantum yields for the photosensitized formation of the lowest electronically excited singlet state of molecular oxygen in solution. J Phys Chem Ref Data 1993 22 : 113 263.
17. Kamuhabwa AR, Geboes KR, de Witte PA. Investigation of the absorption of hypericin into the skin of hairless mice. J Pharm Pharmacol 2000 52 : 487 94.
18. Chen B, Zupko I, de Witte PA. Photodynamic therapy with hypericin in a mouse P388 tumor model: vascular effects determine the efficacy. Int J Oncol 2001 18 : 737 42.
19. Dougherty TJ, Cooper MT, Mang TS. Cutaneous phototoxic occurrences in patients receiving Photofrin. Lasers Surg Med 1990 10 : 485 8.
20. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B Biol 1990 6 : 143 8.
21. Uzdensky AB, Iani V, Ma L-W, Moan J. Photobleaching of hypericin bound to human serum albumin, cultured adenocarcinoma cells and nude mice skin. Photochem Photobiol 2002 76 : 320 8.
22. Vandenbogaerde AL, Geboes KR, Cuveele JF et al. Antitumour activity of photosensitized hypericin on A431 cell xenografts. Anticancer Res 1996 16 : 1619 26.
23. Kamuhabwa AR, Agostinis PM, D'Hallewin M-A et al. Cellular photodestruction induced by hypericin in AY-27 rat bladder carcinoma cells. Photochem Photobiol 2001 74 : 126 32.
24. Chen B, Xu Y, Roskams T et al. Efficacy of antitumoral photodynamic therapy with hypericin: relationship between biodistribution and photodynamic effects in the RIF-1 mouse tumor model. Int J Cancer 2001 93 : 275 82.
25. Bellnier DA, Dougherty TJ. The time course of cutaneous porphyrin photosensitization in the murine ear. Photochem Photobiol 1989 49 : 369 72.
26. Lin GC, Tsoukas ML, Lee MS et al. Skin necrosis due to photodynamic action of benzoporphyrin depends on circulating rather than tissue drug levels: implications for control of photodynamic therapy. Photochem Photobiol 1998 68 : 575 83.
27. Sambuco CP, Forbes PD. Quantitative assessment of phototoxicity in the skin of hairless mice. Food Chem Toxicol 1984 22 : 233 6.
28. Gerberick GF, Ryan CA. A predictive mouse ear-swelling model for investigating topical phototoxicity. Food Chem Toxicol 1989 27 : 813 19.
29. Hawkins CW, Bickers DR, Mukhtar H, Elmets CA. Cutaneous porphyrin photosensitization: murine ear swelling as a marker of the acute response. J Invest Dermatol 1986 86 : 638 42.
30. Zhou C, Yang W, Ding Z et al. The biological effects of photodynamic therapy on normal skin in mice - I. A light microscopic study. Adv Exp Med Biol 1985 193 : 105 9.
31. Divaris DXG, Kennedy JC, Pottiers RH. Phototoxic damage to sebaceous glands and hair follicles of mice after systemic administration of 5-aminolevulinic acid correlates with localized protoporphyrin IX fluorescence. Am J Pathol 1990 136 : 891 7.
32. Kassab K, Fabris C, Defilippis MP et al. Skin photosensitizing properties of Zn(II)-2(3), 9(10), 16(17), 23(24)-tetrakis-(4-oxy-N-methylpiperidinyl) phthalocyanine topically administered to mice. J Photochem Photobiol B Biol 2000 55 : 128 37.
33. Gould JW, Mercurio MG, Elmets CA. Cutaneous photosensitivity diseases induced by exogenous agents. J Am Acad Dermatol 1995 33 : 551 73.
34. Sitnik TM, Henderson BW. The effect of fluence rate on tumor and normal tissue responses to photodynamic therapy. Photochem Photobiol 1998 67 : 462 6.
35. Kennedy JC, Pottier RH. Endogeneous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol B Biol 1992 14 : 275 92.
36. Anderson C, Hrabovsky S, McKinley Y et al. Phthalocyanine photodynamic therapy: disparate effects of pharmacologic inhibitors on cutaneous photosensitivity and on tumor regression. Photochem Photobiol 1997 65 : 895 901.
37. Fritsch C, Homey B, Stahl W et al. Preferential relative porphyrin enrichment in solar keratoses upon topical application of delta-aminolevulinic acid methylester. Photochem Photobiol 1998 68 : 218 21.
38. De Gruijl FR, Van Der Meer JB, Van Der Leun JC. Dose-time dependency of tumor formation by chronic UV exposure. Photochem Photobiol 1983 37 : 53 62.
39. Van Der Veen N, De Bruijn HS, Star WM. Photobleaching during and re-appearance after photodynamic therapy of topical ALA-induced fluorescence in UVB treated mouse skin. Int J Cancer 1997 72 : 110 18.